Arcellx (NASDAQ:ACLX) Lowered to Hold Rating by Leerink Partners

Arcellx (NASDAQ:ACLX) was downgraded by Leerink Partners from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Other analysts have also issued research reports about the company. Truist Financial set a $120.00 price objective on Arcellx in a report on Monday. Canaccord Genuity Group set a $115.00 price objective on shares of Arcellx in a report on Monday. Robert W. Baird restated a “neutral” rating and issued a $115.00 target price (up from $106.00) on shares of Arcellx in a research note on Monday. William Blair cut Arcellx from a “strong-buy” rating to a “hold” rating in a research report on Monday. Finally, Evercore set a $115.00 price objective on Arcellx in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $111.64.

Arcellx Stock Down 0.0%

NASDAQ ACLX opened at $113.71 on Monday. The firm has a market cap of $6.57 billion, a PE ratio of -28.93 and a beta of 0.36. Arcellx has a 52 week low of $47.86 and a 52 week high of $114.26. The company has a 50 day moving average price of $68.84 and a 200 day moving average price of $75.38.

Insiders Place Their Bets

In other Arcellx news, insider Christopher Heery sold 5,882 shares of Arcellx stock in a transaction dated Wednesday, January 14th. The stock was sold at an average price of $68.51, for a total transaction of $402,975.82. Following the completion of the transaction, the insider owned 23,749 shares in the company, valued at approximately $1,627,043.99. This trade represents a 19.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 19,450 shares of company stock worth $1,283,477. 8.35% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Schroder Investment Management Group acquired a new position in shares of Arcellx in the 2nd quarter valued at $3,951,000. Monaco Asset Management SAM acquired a new stake in Arcellx during the third quarter valued at $6,452,000. Pathway Capital Management LP purchased a new position in Arcellx in the third quarter valued at $4,191,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Arcellx in the third quarter worth about $1,273,000. Finally, American Century Companies Inc. boosted its stake in shares of Arcellx by 694.3% during the 2nd quarter. American Century Companies Inc. now owns 431,466 shares of the company’s stock worth $28,412,000 after acquiring an additional 377,145 shares in the last quarter. 96.03% of the stock is owned by institutional investors and hedge funds.

More Arcellx News

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead Sciences agreed to acquire Arcellx for $115.00 per share in cash plus one contingent value right worth $5.00 if milestones are met, implying up to ~$7.8 billion — a takeover premium that drove a large rally. Gilead acquisition release
• Positive Sentiment: Market reaction: the deal triggered a premarket surge (roughly 75–80% intraday move at announcement) and sharply elevated trading volumes as the market re‑priced ACLX to reflect the cash consideration. Reuters coverage
• Neutral Sentiment: HC Wainwright updated FY2030 EPS expectations materially (analyst projects $4.95/sh) but kept a “Neutral” rating and $115 price objective — effectively aligned with the deal price and not implying incremental upside beyond the offer. MarketBeat report
• Negative Sentiment: Multiple brokerages downgraded ACLX to “hold”/”equal weight” (Truist, Baird, Canaccord, Needham, Wells Fargo, Citigroup), signaling limited upside above the deal price and reducing buy‑side conviction. Example coverage: Truist/Benzinga. Benzinga downgrades roundup
• Negative Sentiment: Several law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Monteverde) announced investigations into whether the $115 + $5 CVR consideration is fair — potential litigation could seek a higher price, delay closing or increase transaction risk/uncertainty. KSF investor alert

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.